Bottom line: Very good news on the medical front yesterday as trial results show Remdesivir can lower the mortality rate of COVID-19 and that the dose needed is smaller than initially expected. In terms of the virus numbers, the improvement in Europe and the US has paused in recent days but it probably reflects normal fluctuations. Some countries still bear watching such as Brazil, Nigeria and Bangladesh. India and Peru also still struggle to get the outbreak under control.


Read the full article on Danske Bank Research's website here.